Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

67.4K
Overview
67.4K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2
Hypersensitivities01:30

Hypersensitivities

529
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
529
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maralixibat for PFIC.

Canadian liver journal·2026
Same author

Neighborhood-Level Material Resources and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease.

The Canadian journal of cardiology·2026
Same author

Patient-physician familiarity is just as important for virtual outpatient encounters as for in-person encounters: a retrospective cohort study.

Scientific reports·2026
Same author

The Burden of Cardiovascular Disease in Lymphoma Survivors: A Population-Based Matched Cohort Study.

JACC. Advances·2026
Same author

Evaluating the temporal and sociodemographic generalizability of the emergency heart failure mortality risk grade.

ESC heart failure·2026
Same author

Machine Learning Model Using Pre-Cancer Therapy Cardiac Magnetic Resonance Images to Predict Cancer Therapy-Related Cardiac Dysfunction.

JACC. Cardiovascular imaging·2026

Related Experiment Video

Updated: Jun 9, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.

Parneet K Cheema1, Marco A J Iafolla1, Husam Abdel-Qadir2,3

  • 1William Osler Health System, Brampton, ON L6R 3J7, Canada.

Current Oncology (Toronto, Ont.)
|October 25, 2024
PubMed
Summary

Standardized management of immune-related adverse events (irAEs) is crucial with increased use of immune checkpoint inhibitors (ICIs). This study outlines practical, multidisciplinary approaches for early recognition, assessment, and treatment of irAEs in cancer care.

Keywords:
immune checkpoint inhibitorsimmune-related adverse eventsimmunosuppressants

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

296
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Related Experiment Videos

Last Updated: Jun 9, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

296
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Area of Science:

  • Oncology
  • Immunology
  • Clinical Medicine

Background:

  • Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy.
  • Immune-related adverse events (irAEs) require standardized monitoring and management.
  • Existing guidelines offer high-level recommendations but lack practical, institutional guidance.

Purpose of the Study:

  • To describe a practical, step-by-step multidisciplinary approach for managing irAEs.
  • To provide algorithms and recommendations for healthcare providers caring for patients on ICIs.
  • To facilitate early recognition, assessment, and treatment of irAEs.

Main Methods:

  • Development of institutional protocols and algorithms for irAE management.
  • Collaboration between multidisciplinary specialists across Canada.
  • Detailed outlining of baseline investigations, monitoring, and treatment based on irAE characteristics.

Main Results:

  • A practical framework for managing irAEs was developed at William Osler Health System.
  • The approach includes baseline investigations, monitoring, and treatment strategies.
  • Recommendations are tailored to symptoms, severity, and organ systems involved.

Conclusions:

  • Standardized, multidisciplinary protocols are essential for effective irAE management.
  • The described approach can be adapted by other institutions to improve patient care.
  • Timely and collaborative management of irAEs is critical for patient safety and treatment efficacy.